Developer docs
API playgroundTry for free, no card

Search company profiles

Vimy Pharma

Full company profile

uuid003wc72

Namestring
Vimy Pharma
Legal namestring
Vimy Pharmaceuticals Inc.
Websiteurl
vimypharma.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Vimy Pharma (legal name Vimy Pharmaceuticals Inc.) is a privately held Canadian pharmaceutical manufacturer founded in 2024 and headquartered in Toronto. The company develops and intends to produce high-quality, affordable complex medicines, with its lead and currently only disclosed product being a generic version of semaglutide (generic Ozempic), a GLP-1 receptor agonist indicated for diabetes and obesity. Manufacturing is planned for Canadian facilities (with Edmonton referenced in coverage) under Health Canada quality standards, and the company frames its positioning explicitly around Canadian-made and Canadian-owned production to reduce dependence on foreign pharmaceutical supply.

The business model is product sales of generic pharmaceuticals distributed through a single channel partner: Vimy has outsourced all sales and marketing activities across Canada to Pharmaris Canada under a strategic partnership announced 2025-05-30, giving Vimy nationwide reach without an internal salesforce. End customers are Canadian patients with chronic diseases (diabetes and obesity) and the broader publicly funded healthcare system, with secondary stakeholders including employer plan sponsors bearing the cost of specialty medications. Revenue is not yet generated as products are in development and have not launched; pricing has not been disclosed.

The company is led by co-founders with deep GLP-1 and pharmaceutical finance backgrounds: CEO Dave Suchon (former VP Corporate Affairs at Novo Nordisk Canada who led the first Canadian Ozempic approval in 2018), President and Chair Farris Smith (former CFO at Novo Nordisk and LEO Pharma North America), and COO Chris Burkett (former National Leader, Legal at Deloitte Canada). The board includes operators with pharma (Patheon/Thermo Fisher), real estate, and legal backgrounds. The company has also established a community partnership with Wounded Warriors Canada, pledging a portion of profits, and recorded a funding round with K2 & Associates in October 2025.

Short descriptiontext

Vimy Pharma is a Toronto-based private pharmaceutical manufacturer developing a Canadian-made generic version of semaglutide (generic Ozempic) for diabetes and obesity, distributing exclusively through partner Pharmaris Canada to serve Canadian patients and the publicly funded healthcare system.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals manufacturing, GLP-1 receptor agonists, semaglutide generic drugs, diabetes obesity treatments, complex medicine manufacturing
Industry2 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue generated through the sale of generic pharmaceutical products, primarily targeting the Canadian domestic market. The company focuses on essential medicines for chronic diseases including diabetes and obesity.

vimypharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vimy Pharma is a Canadian pharmaceutical manufacturer developing and producing a generic version of semaglutide (generic Ozempic), a GLP-1 therapy indicated for the treatment of type 2 diabetes and obesity. The company focuses on Canadian-made, Canadian-owned manufacturing of complex medicines that meet Health Canada quality and safety guidelines, with sales and marketing executed nationally through a partnership with Pharmaris Canada.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Goal of providing affordable access to essential medicines for millions of Canadians
Product overview1 text field

Vimy Pharma is a proudly Canadian pharmaceutical company developing and manufacturing high-quality, affordable essential medicines. The company's primary focus is producing a generic version of Ozempic (generic semaglutide) — a GLP-1 medication for diabetes and obesity treatment. The product portfolio centers on this single pharmaceutical offering, with manufacturing planned for Canadian facilities (potentially Edmonton) and sales/marketing handled through a partnership with Pharmaris Canada across Canada.

Product and service1 record
1Generic Semaglutide (Generic Ozempic)
CategoryGeneric Pharmaceuticals (GLP-1 receptor agonist)
Description

A generic version of the blockbuster GLP-1 therapy Ozempic (semaglutide), being developed and manufactured in Canada as a high-quality, affordable treatment for type 2 diabetes and obesity. Targeted at the Canadian domestic market and distributed through a sales and marketing partnership with Pharmaris Canada.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-07-08
Description

Vimy Pharma announced a partnership with Wounded Warriors Canada, a national leader in mental health services for Veterans, First Responders, and their families. Under this partnership, Vimy Pharma pledges a portion of its profits to support the organization. The partnership reflects Vimy Pharma's commitment to Canadian communities and honors the military heritage reflected in the company's name (Vimy Ridge).

2Pharmaris Canada
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-05-30
Description

Pharmaris Canada and Vimy Pharma announced a strategic partnership in which Pharmaris will assume responsibility for all sales and marketing activities for Vimy Pharma's product portfolio across Canada. The collaboration unites two Canadian pharmaceutical organizations with the stated goal of strengthening domestic pharmaceutical capabilities and improving access to essential medicines for Canadian patients. Both companies emphasized their commitment to making healthcare more accessible and affordable from coast to coast.

finance.yahoo.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

CDMO acquired by Thermo Fisher with deep expertise in complex pharmaceutical manufacturing including peptides. Comparable as a potential manufacturing partner or contract manufacturer for Vimy's complex generic portfolio, and a connection through Vimy board member Riccardo Trecroce (former Patheon CEO).

TypeDirect peer
Description

Canada's largest generic pharmaceutical manufacturer, producing a broad portfolio of generic medicines including complex generics. Directly comparable as a Canadian-based competitor that will likely pursue generic semaglutide and competes for the same domestic payer and patient market.

TypeDirect peer
Description

Canadian arm of one of the world's largest generic drug makers, with a strong portfolio in chronic disease. Comparable as a likely entrant into generic semaglutide in Canada and a benchmark for scale and pricing pressure in the Canadian generic market.

TypeEmerging player
Description

Canadian specialty pharmaceutical company focused on commercializing products in chronic disease categories. Comparable to Vimy as a small-to-mid Canadian pharma pursuing specialty and complex generics in similar therapeutic areas.

TypeDirect peer
Description

Major Canadian-owned generic pharmaceutical manufacturer with domestic production capabilities. Comparable to Vimy Pharma as a Canadian-headquartered generic manufacturer targeting the same domestic market with similar chronic-disease therapeutic categories.

6Novo Nordisk Canada
TypeBroad incumbent
Description

Innovator of Ozempic (semaglutide) and the dominant GLP-1 player in Canada. Comparable as the incumbent whose patents Vimy is targeting and whose commercial footprint, KOL relationships, and pricing power set the benchmark for any generic entrant.

TypeDirect peer
Description

Canadian division of Sandoz, a global leader in generics and biosimilars. Directly comparable as a large-scale competitor in Canadian generic pharmaceuticals, particularly relevant given Sandoz's leadership in biosimilars and complex generics.

TypeRegional player
Description

Canadian operations of a major India-based global generic manufacturer. Comparable as a likely global generic entrant into Canadian semaglutide with deep manufacturing scale that could undercut Vimy on price.

TypeEmerging player
Description

Canadian specialty pharmaceutical company focused on commercializing late-stage products in cardiovascular and CNS. Comparable as a Canadian-headquartered specialty pharma with similar scale and commercial-stage focus on chronic disease.

TypeBroad incumbent
Description

Canadian arm of Eli Lilly, maker of competing GLP-1 therapies (Mounjaro/Zepbound). Comparable as a broad incumbent in the same therapeutic category and a major competitor for the Canadian diabetes/obesity market that Vimy targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vimy Pharma

Generic Pharmaceuticalsvimypharma.com

Vimy Pharma is a Toronto-based private pharmaceutical manufacturer developing a Canadian-made generic version of semaglutide (generic Ozempic) for diabetes and obesity, distributing exclusively through partner Pharmaris Canada to serve Canadian patients and the publicly funded healthcare system.

What Vimy Pharma does

Vimy Pharma (legal name Vimy Pharmaceuticals Inc.) is a privately held Canadian pharmaceutical manufacturer founded in 2024 and headquartered in Toronto. The company develops and intends to produce high-quality, affordable complex medicines, with its lead and currently only disclosed product being a generic version of semaglutide (generic Ozempic), a GLP-1 receptor agonist indicated for diabetes and obesity. Manufacturing is planned for Canadian facilities (with Edmonton referenced in coverage) under Health Canada quality standards, and the company frames its positioning explicitly around Canadian-made and Canadian-owned production to reduce dependence on foreign pharmaceutical supply.

The business model is product sales of generic pharmaceuticals distributed through a single channel partner: Vimy has outsourced all sales and marketing activities across Canada to Pharmaris Canada under a strategic partnership announced 2025-05-30, giving Vimy nationwide reach without an internal salesforce. End customers are Canadian patients with chronic diseases (diabetes and obesity) and the broader publicly funded healthcare system, with secondary stakeholders including employer plan sponsors bearing the cost of specialty medications. Revenue is not yet generated as products are in development and have not launched; pricing has not been disclosed.

The company is led by co-founders with deep GLP-1 and pharmaceutical finance backgrounds: CEO Dave Suchon (former VP Corporate Affairs at Novo Nordisk Canada who led the first Canadian Ozempic approval in 2018), President and Chair Farris Smith (former CFO at Novo Nordisk and LEO Pharma North America), and COO Chris Burkett (former National Leader, Legal at Deloitte Canada). The board includes operators with pharma (Patheon/Thermo Fisher), real estate, and legal backgrounds. The company has also established a community partnership with Wounded Warriors Canada, pledging a portion of profits, and recorded a funding round with K2 & Associates in October 2025.

Vimy Pharma firmographics

Firmographics
Name
Vimy Pharma
Legal name
Vimy Pharmaceuticals Inc.
Website
https://vimypharma.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Vimy Pharma is a Toronto-based private pharmaceutical manufacturer developing a Canadian-made generic version of semaglutide (generic Ozempic) for diabetes and obesity, distributing exclusively through partner Pharmaris Canada to serve Canadian patients and the publicly funded healthcare system.
Ownership category
akta.pro rank

Vimy Pharma industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Generic pharmaceuticals manufacturing
  • GLP-1 receptor agonists
  • Semaglutide generic drugs
  • Diabetes obesity treatments
  • Complex medicine manufacturing

Where Vimy Pharma is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Vimy Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Revenue generated through the sale of generic pharmaceutical products, primarily targeting the Canadian domestic market. The company focuses on essential medicines for chronic diseases including diabetes and obesity.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Vimy Pharma product offering

Product offering

Core offering

Vimy Pharma is a Canadian pharmaceutical manufacturer developing and producing a generic version of semaglutide (generic Ozempic), a GLP-1 therapy indicated for the treatment of type 2 diabetes and obesity. The company focuses on Canadian-made, Canadian-owned manufacturing of complex medicines that meet Health Canada quality and safety guidelines, with sales and marketing executed nationally through a partnership with Pharmaris Canada.

Product overview

Vimy Pharma is a proudly Canadian pharmaceutical company developing and manufacturing high-quality, affordable essential medicines. The company's primary focus is producing a generic version of Ozempic (generic semaglutide) — a GLP-1 medication for diabetes and obesity treatment. The product portfolio centers on this single pharmaceutical offering, with manufacturing planned for Canadian facilities (potentially Edmonton) and sales/marketing handled through a partnership with Pharmaris Canada across Canada.

Differentiator

Problem solved

Functional benefit

Products and services

  • Generic Semaglutide (Generic Ozempic) A generic version of the blockbuster GLP-1 therapy Ozempic (semaglutide), being developed and manufactured in Canada as a high-quality, affordable treatment for type 2 diabetes and obesity. Targeted at the Canadian domestic market and distributed through a sales and marketing partnership with Pharmaris Canada.

Quantifiable outcome

  • Goal of providing affordable access to essential medicines for millions of Canadians

Companies that use Vimy Pharma

Customer profile

Segments3 records

Ideal customer profiles3 records

Vimy Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Vimy Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Wounded Warriors CanadaminorGTM or Marketing Partner · 8 July 2025Vimy Pharma announced a partnership with Wounded Warriors Canada, a national leader in mental health services for Veterans, First Responders, and their families. Under this partnership, Vimy Pharma pledges a portion of its profits to support the organization. The partnership reflects Vimy Pharma's commitment to Canadian communities and honors the military heritage reflected in the company's name (Vimy Ridge).
  • Pharmaris CanadacoreChannel Partner/ Reseller/ Distributor · 30 May 2025Pharmaris Canada and Vimy Pharma announced a strategic partnership in which Pharmaris will assume responsibility for all sales and marketing activities for Vimy Pharma's product portfolio across Canada. The collaboration unites two Canadian pharmaceutical organizations with the stated goal of strengthening domestic pharmaceutical capabilities and improving access to essential medicines for Canadian patients. Both companies emphasized their commitment to making healthcare more accessible and affordable from coast to coast.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Vimy Pharma competitors and assessment

Company assessment

Others

  • Patheon (Thermo Fisher Scientific): CDMO acquired by Thermo Fisher with deep expertise in complex pharmaceutical manufacturing including peptides. Comparable as a potential manufacturing partner or contract manufacturer for Vimy's complex generic portfolio, and a connection through Vimy board member Riccardo Trecroce (former Patheon CEO).

Direct peers

  • Apotex: Canada's largest generic pharmaceutical manufacturer, producing a broad portfolio of generic medicines including complex generics. Directly comparable as a Canadian-based competitor that will likely pursue generic semaglutide and competes for the same domestic payer and patient market.
  • Teva Canada: Canadian arm of one of the world's largest generic drug makers, with a strong portfolio in chronic disease. Comparable as a likely entrant into generic semaglutide in Canada and a benchmark for scale and pricing pressure in the Canadian generic market.
  • Pharmascience: Major Canadian-owned generic pharmaceutical manufacturer with domestic production capabilities. Comparable to Vimy Pharma as a Canadian-headquartered generic manufacturer targeting the same domestic market with similar chronic-disease therapeutic categories.
  • Sandoz Canada: Canadian division of Sandoz, a global leader in generics and biosimilars. Directly comparable as a large-scale competitor in Canadian generic pharmaceuticals, particularly relevant given Sandoz's leadership in biosimilars and complex generics.

Emerging players

  • Cipher Pharmaceuticals: Canadian specialty pharmaceutical company focused on commercializing products in chronic disease categories. Comparable to Vimy as a small-to-mid Canadian pharma pursuing specialty and complex generics in similar therapeutic areas.
  • HLS Therapeutics: Canadian specialty pharmaceutical company focused on commercializing late-stage products in cardiovascular and CNS. Comparable as a Canadian-headquartered specialty pharma with similar scale and commercial-stage focus on chronic disease.

Broad incumbents

  • Novo Nordisk Canada: Innovator of Ozempic (semaglutide) and the dominant GLP-1 player in Canada. Comparable as the incumbent whose patents Vimy is targeting and whose commercial footprint, KOL relationships, and pricing power set the benchmark for any generic entrant.
  • Eli Lilly Canada: Canadian arm of Eli Lilly, maker of competing GLP-1 therapies (Mounjaro/Zepbound). Comparable as a broad incumbent in the same therapeutic category and a major competitor for the Canadian diabetes/obesity market that Vimy targets.

Regional players

  • Dr. Reddy's Laboratories Canada: Canadian operations of a major India-based global generic manufacturer. Comparable as a likely global generic entrant into Canadian semaglutide with deep manufacturing scale that could undercut Vimy on price.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Vimy Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vimy Pharma leadership team

Management profile

Number of profiles

Profiles5 records

Vimy Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vimy Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vimy Pharma

What does Vimy Pharma do?

Vimy Pharma is a Canadian pharmaceutical manufacturer developing and producing a generic version of semaglutide (generic Ozempic), a GLP-1 therapy indicated for the treatment of type 2 diabetes and obesity. The company focuses on Canadian-made, Canadian-owned manufacturing of complex medicines that meet Health Canada quality and safety guidelines, with sales and marketing executed nationally through a partnership with Pharmaris Canada.

Is Vimy Pharma a public or private company?

Vimy Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Vimy Pharma founded?

Vimy Pharma was founded in 2024. It employs 1 to 10 people.

Where is Vimy Pharma based?

Vimy Pharma is headquartered in Toronto, Canada, in the North America region.

How does Vimy Pharma make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Vimy Pharma's main competitors?

Patheon (Thermo Fisher Scientific) is listed as an others. Direct peers are Apotex, Teva Canada, Pharmascience and Sandoz Canada. Emerging players are Cipher Pharmaceuticals and HLS Therapeutics. Broad incumbents are Novo Nordisk Canada and Eli Lilly Canada. Dr. Reddy's Laboratories Canada is listed as a regional player.

Does Vimy Pharma have an API?

No public API is recorded for Vimy Pharma.

What industry is Vimy Pharma in?

Vimy Pharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewsfileVimy Pharmaceuticals Corp. (VIMY) ouvre les marchésVimy Pharmaceuticals Corp. opened markets on the TSXV, led by its executives and TSX client success chief Omar Khafagy. The company develops generic essential medicines to strengthen Canadian pharmaceutical manufacturing and supply resilience. It aims to create a sustainable national pharmaceutical ecosystem.NewsfileVimy Pharmaceuticals Corp. (VIMY) Opens the MarketVimy Pharmaceuticals Corp. opened the market on the TSX Venture Exchange, with executives joining TSX officials to celebrate the listing. The company aims to expand domestic pharmaceutical manufacturing and supply resilience, advancing a portfolio of generic essential medicines.AktienVimy Pharmaceuticals Corp. (VIMY) Opens the MarketVimy Pharmaceuticals Corp. opened the market on the TSX Venture Exchange on November 17, 2026, with executives and TSX officials. The company aims to expand domestic pharmaceutical manufacturing capacity and long-term Canadian supply resilience. It is advancing a portfolio of essential generic medicines.Dealroom.coVimy Pharmaceuticals lists on TSXV after US$10.6M raise | Dealroom NewsVimy Pharmaceuticals completed a US$10.7M late-stage financing and its qualifying transaction with Harmony Acquisitions Corp., clearing the way for a TSX Venture Exchange debut expected on November 17, 2026. The Canadian generic medicines company's lead program is generic semaglutide, with proceeds earmarked for product development, Canadian manufacturing, and market expansion.NewswireTHE K2 PRINCIPAL FUND L.P. UPDATED HOLDINGS IN VIMY PHARMACEUTICALS CORP.The K2 Principal Fund acquired 7,990,642 Vimy Pharmaceuticals shares on November 12, 2026, representing about 24.70% of the company. The shares are subject to escrow and transfer restrictions, and K2 holds nomination rights to appoint a board nominee.NewsfileVimy Pharma Completes Qualifying TransactionVimy Pharmaceuticals Corp. completed its business combination with Vimy Pharma via a three-cornered amalgamation, with shares trading under 'VIMY' on the TSXV. The company now has 32,347,829 Resulting Issuer Shares outstanding, and the Vimy Pharma Financing proceeds will fund R&D and commercialization.AktienVimy Pharma Completes Qualifying TransactionVimy Pharmaceuticals Corp. completed its business combination with Vimy Pharma via a three-cornered amalgamation. The resulting issuer will trade on the TSXV under 'VIMY' on November 17, 2026, with 32,347,829 shares outstanding. An escrow agreement for 22,535,642 shares was also entered into.Dealroom.coVimy Pharma clears TSXV hurdle in reverse takeover built on generic Ozempic betVimy Pharma and Harmony Acquisitions won conditional TSXV approval for a reverse takeover, with closing expected around November 12. Vimy plans to trade as Vimy Pharmaceuticals Corp. and has filed Health Canada submissions for generic Ozempic and Wegovy, targeting Canada's $3.5B semaglutide market.NewsfileVimy Pharmaceuticals Announces Closing of $12 Million Brokered Private Placement of Subscription Receipts, Filing of TSXV Listing Application and Execution of Definitive AgreementVimy Pharmaceuticals closed a $12 million brokered private placement of 4,018,821 subscription receipts at $3.00 each, and filed a TSXV listing application for its reverse takeover of Harmony. Proceeds will fund R&D, including its generic semaglutide program, and the transaction is expected to close by end of October 2026.AktienVimy Pharmaceuticals Announces Closing of $12 Million Brokered Private Placement of Subscription Receipts, Filing of TSXV Listing Application and Execution of Definitive AgreementVimy Pharmaceuticals closed a $12 million brokered private placement of subscription receipts at $3.00 each, raising $12,056,463. The company filed a TSXV listing application for the reverse takeover of Harmony, with completion expected in October 2026. Proceeds will fund R&D, including its generic semaglutide program.